Effects of yeast β-glucans for the prevention and treatment of upper respiratory tract infection in healthy subjects: a systematic review and meta-analysis

• Published in: European journal of nutrition Vol. 60; no. 8; pp. 4175 - 4187
• Main Authors: Zhong, Kunxia, Liu, Zhiqin, Lu, Yao, Xu, Xi
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2021; Springer Nature B.V
• Subjects: beta-Glucans; Chemistry; Chemistry and Materials Science; Clinical trials; Disease prevention; Glucans; Healthy Volunteers; Humans; Immunomodulation; immunomodulators; Incidence; Infections; Meta-analysis; Nutrition; Placebos; Respiratory diseases; respiratory system; Respiratory tract diseases; Respiratory tract infection; Respiratory Tract Infections - prevention & control; Review; Saccharomyces cerevisiae; Systematic review; Yeast; yeasts; β-Glucan; Healthy subjects; Systematic review; Yeast β-glucan; Upper respiratory tract infection; Meta-analysis
• ISSN: 1436-6207; 1436-6215; 1436-6215
• DOI: 10.1007/s00394-021-02566-4

Purpose Yeast β-glucans are known for their immune-modulating effects; however, their effects on human upper respiratory tract infections (URTIs) remain unclear. The aim of the present study was to use a systematic review and meta-analysis approach to investigate the effects of yeast β-glucans for the prevention and treatment of URTIs in healthy subjects. Methods Databases including Pubmed, Web of Science, EMBASE and the Cochrane Library were searched and 13 RCTs investigating the effects of yeast β-glucans on the incidence, duration, and severity of URTIs in healthy subjects were included. Results The results showed that compared to the placebo group, yeast β-glucan could significantly reduce the incidence of URTIs (OR = 0.345, 95% CI = 0.192 to 0.620, p  < 0.001), decrease the average number of URTI episodes (SMD =  − 0.315, 95% CI =  − 0.500 to  − 0.130, p  < 0.05), and decrease the duration of URTIs (SMD =  − 0.312, 95% CI =  − 0.561 to  − 0.064, p  < 0.001). Improved severity of symptoms was found in yeast β-glucan group compared to the placebo group in the majority of included studies. In addition, yeast β-glucan was well tolerated and safe in general. Conclusion These findings suggest a positive effect of yeast β-glucans on human URTIs. However, due to the high heterogeneity and small number of included studies, more high-quality research and clinical trials are warranted.